Search This Blog

Wednesday, September 9, 2026

Evommune to discontinue EVO756 for atopic dermatitis after failed Phase 2b trial, refocus on migraine

 

Evommune to discontinue EVO756 for atopic dermatitis after failed Phase 2b trial, refocuses program on migraine prophylaxis


  • Company disclosed decision and top-line Phase 2b EVO756 data for moderate-to-severe atopic dermatitis in an SEC filing.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)